Cross-sectional studies of patients with systemic lupus erythematosus (SLE) have demonstrated an association between activation of type I interferon (IFN) pathway and disease activity. This study examined longitudinal changes in IFN-regulated gene expression in peripheral blood using microarrays. A cross-section of 66 patients from the Autoimmune Biomarkers Collaborative Network SLE archive was evaluated. We also examined paired samples from a 15 patient subset collected during a period of low disease activity (Baseline) and at a subsequent flare event, and baseline scores of 29 patients who maintained low disease activity. IFN response (IFNr) scores were calculated from three IFN-regulated genes. Overall, higher IFNr scores were associated with increased disease activity. However, IFNr scores were not significantly different between the paired Baseline and Flare samples. An extended longitudinal analysis in 11 patients indicated little change in IFNr scores over time, even during dynamic disease activity. In patients with low disease activity, IFNr scores were not different between patients who experienced a subsequent flare and those who maintained low disease activity. In summary, although higher IFNr scores were associated with greater disease activity, IFNr scores of individual patients did not correlate with changes in disease severity or flare risk.
2 Jacobi AM Diamond B . Balancing diversity and tolerance: lessons from patients with systemic lupus erythematosus. J Exp Med2005; 202: 341–344.
3.
3 Lipsky PE . Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol2001; 2: 764–766.
4.
4 Hooks JJ Moutsopoulos HM Geis SA Stahl NI Decker JL Notkins AL . Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med1979; 301: 5–8.
5.
5 Baechler EC Batliwalla FM Karypis G . Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A2003; 100: 2610–2615.
6.
6 Bennett L Palucka AK Arce E . Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med2003; 197: 711–723.
7.
7 Kirou KA Lee C George S Louca K Peterson MG Crow MK . Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum2005; 52: 1491–1503.
8.
8 Nikpour M Dempsey AA Urowitz MB Gladman DD Barnes DA . Association of a gene expression profile from whole blood with disease activity in systemic lupus erythematosus.Ann Rheum Dis2007; 67: 1069–1087.
9.
9 Hua J Kirou K Lee C Crow MK . Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum2006; 54: 1906–1916.
10.
10 Bauer JW Baechler EC Petri M . Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med2006; 3: e491.
11.
11 Savarese E Chae OW Trowitzsch S . U1 small nuclear ribonucleoprotein immune complexes induce type I interferon in plasmacytoid dendritic cells through TLR7. Blood2006; 107: 3229–3234.
12.
12 Vallin H Blomberg S Alm GV Cederblad B Ronnblom L . Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon-alpha (IFN-alpha) production acting on leucocytes resembling immature dendritic cells. Clin Exp Immunol1999; 115: 196–202.
13.
13 Baechler EC Gregersen PK Behrens TW . The emerging role of interferon in human systemic lupus erythematosus. Curr Opin Immunol2004; 16: 801–807.
14.
14 Schmidt KN Ouyang W . Targeting interferon-alpha: a promising approach for systemic lupus erythematosus therapy. Lupus2004; 13: 348–352.
15.
15 Graham RR Kozyrev SV Baechler EC . A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet2006; 38: 550–555.
16.
16 Graham RR Kyogoku C Sigurdsson S . Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proc Natl Acad Sci U S A2007; 104: 6758–6763.
17.
17 Gota C Calabrese L . Induction of clinical autoimmune disease by therapeutic interferon-alpha. Autoimmunity2003; 36: 511–518.
18.
18 MacDermott EJ Cherian J Santiago AG . Type 1 interferon pathway activation predicts flares of disease activity in SLE. Arthritis Rheum2008; 58: 3974–3975.
19.
19 Landolt-Marticorena C Bonventi G Lubovich A . Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus.Ann Rheum Dis2008.
20.
20 Niewold TB Hua J Lehman TJ Harley JB Crow MK . High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun2007; 8: 492–502.
21.
21 Petri M . Hopkins Lupus Cohort. 1999 update. Rheum Dis Clin North Am2000; 26: 199–213 v.
22.
22 Petri M Kim MY Kalunian KC . Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med2005; 353: 2550–2558.
23.
23 Symmons DP Coppock JS Bacon PA . ; Members of the British Isles Lupus Assessment Group (BILAG).Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Q J Med1988; 69: 927–937.
24.
24 Gladman DD Urowitz MB Kagal A Hallett D . Accurately describing changes in disease activity in systemic lupus erythematosus. J Rheumatol2000; 27: 377–379.
25.
25 Han GM Chen SL Shen N . Analysis of gene expression profiles in human systemic lupus erythematosus using oligonucleotide microarray. Genes Immun2003; 4: 177–186.
26.
26 Hochberg MC . Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997; 40: 1725.
27.
27 Tan EM Cohen AS Fries JF . The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1982; 25: 1271–1277.
28.
28 Bolstad BM Irizarry RA Astrand M Speed TP . A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics2003; 19: 185–193.
29.
29 Kirou KA Lee C George S . Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus. Arthritis Rheum2004; 50: 3958–3967.
30.
30 Feng X Wu H Grossman JM . Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum2006; 54: 2951–2962.
31.
31 Der SD Zhou A Williams BR Silverman RH . Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci U S A1998; 95: 15623–15628.
32.
32 Indraccolo S Pfeffer U Minuzzo S . Identification of genes selectively regulated by IFNs in endothelial cells. J Immunol2007; 178: 1122–1135.
33.
33 Rasmussen UB Wolf C Mattei MG . Identification of a new interferon-alpha-inducible gene (p27) on human chromosome 14q32 and its expression in breast carcinoma. Cancer Res1993; 53: 4096–4101.
34.
34 Ravirajan CT Rowse L MacGowan JR Isenberg DA . An analysis of clinical disease activity and nephritis-associated serum autoantibody profiles in patients with systemic lupus erythematosus: a cross-sectional study. Rheumatology (Oxford)2001; 40: 1405–1412.
35.
35 Shi L Reid LH Jones WD . The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol2006; 24: 1151–1161.
36.
36 Kariuki SN Crow MK Niewold TB . The PTPN22 C1858T polymorphism is associated with skewing of cytokine profiles toward high interferon-alpha activity and low tumor necrosis factor alpha levels in patients with lupus. Arthritis Rheum2008; 58: 2818–2823.
37.
37 Niewold TB Kelly JA Flesch MH Espinoza LR Harley JB Crow MK . Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients. Arthritis Rheum2008; 58: 2481–2487.
38.
38 Whitney AR Diehn M Popper SJ . Individuality and variation in gene expression patterns in human blood. Proc Natl Acad Sci U S A2003; 100: 1896–1901.
39.
39 Mandl JN Barry AP Vanderford TH . Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. Nat Med2008; 14: 1077–1087.
40.
40 Cobb JP Mindrinos MN Miller-Graziano C . Application of genome-wide expression analysis to human health and disease. Proc Natl Acad Sci U S A2005; 102: 4801–4806.
41.
41 Le Bon A Schiavoni G D'Agostino G Gresser I Belardelli F Tough DF . Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity2001; 14: 461–470.
42.
42 Jego G Palucka AK Blanck JP Chalouni C Pascual V Banchereau J . Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity2003; 19: 225–234.
43.
43 Marrack P Kappler J Mitchell T . Type I interferons keep activated T cells alive. J Exp Med1999; 189: 521–530.
